417 related articles for article (PubMed ID: 14567425)
1. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs.
Abadie JJ; Amardeilh MA; Delverdier ME
J Am Vet Med Assoc; 1999 Dec; 215(11):1629-34. PubMed ID: 14567425
[TBL] [Abstract][Full Text] [Related]
2. Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002).
Ettinger SN; Scase TJ; Oberthaler KT; Craft DM; McKnight JA; Leibman NF; Charney SC; Bergman PJ
J Am Vet Med Assoc; 2006 Apr; 228(7):1053-62. PubMed ID: 16579784
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).
Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE
J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175
[TBL] [Abstract][Full Text] [Related]
5. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs.
Schultheiss PC; Gardiner DW; Rao S; Olea-Popelka F; Tuohy JL
J Am Vet Med Assoc; 2011 Jun; 238(11):1464-9. PubMed ID: 21627510
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
Stanclift RM; Gilson SD
J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
[TBL] [Abstract][Full Text] [Related]
7. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
8. Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision.
Scarpa F; Sabattini S; Marconato L; Capitani O; Morini M; Bettini G
J Am Vet Med Assoc; 2012 May; 240(10):1181-7. PubMed ID: 22559107
[TBL] [Abstract][Full Text] [Related]
9. Canine subcutaneous mast cell tumour: diagnosis and prognosis.
Newman SJ; Mrkonjich L; Walker KK; Rohrbach BW
J Comp Pathol; 2007 May; 136(4):231-9. PubMed ID: 17399734
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of proliferating cell nuclear antigen and Ki-67 in malignant ovarian germ cell tumors.
Liu FS; Chen JT; Liu SC; Shih A; Shih RT; Ho ES
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):695-702. PubMed ID: 10533299
[TBL] [Abstract][Full Text] [Related]
11. Nucleomorphometric analysis of canine cutaneous mast cell tumours.
Maiolino P; Cataldi M; Paciello O; Restucci B; De Vico G
J Comp Pathol; 2005; 133(2-3):209-11. PubMed ID: 16045919
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors.
Bodey B; Bodey B; Gröger AM; Siegel SE; Kaiser HE
Anticancer Res; 1997; 17(1A):189-96. PubMed ID: 9066650
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs.
Turrel JM; Kitchell BE; Miller LM; Théon A
J Am Vet Med Assoc; 1988 Oct; 193(8):936-40. PubMed ID: 3142828
[TBL] [Abstract][Full Text] [Related]
14. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
[TBL] [Abstract][Full Text] [Related]
15. PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs.
Roels S; Tilmant K; Ducatelle R
J Comp Pathol; 1999 Jul; 121(1):13-24. PubMed ID: 10373290
[TBL] [Abstract][Full Text] [Related]
16. Morphometry of canine cutaneous mast cell tumors.
Strefezzi Rde F; Xavier JG; Catão-Dias JL
Vet Pathol; 2003 May; 40(3):268-75. PubMed ID: 12724567
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables.
Peña LL; Nieto AI; Pérez-Alenza D; Cuesta P; Castaño M
J Vet Diagn Invest; 1998 Jul; 10(3):237-46. PubMed ID: 9683072
[TBL] [Abstract][Full Text] [Related]
18. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.
Maglennon GA; Murphy S; Adams V; Miller J; Smith K; Blunden A; Scase TJ
Vet Comp Oncol; 2008 Dec; 6(4):268-74. PubMed ID: 19178685
[TBL] [Abstract][Full Text] [Related]
19. Mast cell tumor destruction by deionized water.
Grier RL; Di Guardo G; Schaffer CB; Pedrosa B; Myers R; Merkley DF; Thouvenelle M
Am J Vet Res; 1990 Jul; 51(7):1116-20. PubMed ID: 2117868
[TBL] [Abstract][Full Text] [Related]
20. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Lehmann J; Retz M; Nürnberg N; Schnöckel U; Raffenberg U; Krams M; Kellner U; Siemer S; Weichert-Jacobsen K; Stöckle M
Cancer; 2004 Oct; 101(7):1552-62. PubMed ID: 15378494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
